• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » AtriCure agrees to pay $3 million to settle class-action ablation suit

AtriCure agrees to pay $3 million to settle class-action ablation suit

August 24, 2010 By MedCity News

MedCity News logo

AtriCure Inc. (NSDQ:ATRC) agreed to pay $2.8 million to settle a class-action shareholder lawsuit stemming from claims that it promoted its surgical cardiac ablation devices for unapproved uses.

The proposed class-action settlement follows a settlement by the company in February with the U.S. Dept. of Justice over essentially the same matter. In the DOJ settlement, AtriCure agreed to pay $3.8 million to settle claims that the company marketed its surgical devices as a treatment for atrial fibrillation, despite not having regulatory approval for that condition.

In the proposed $2.8 million settlement, a Cincinnati judge will hold a hearing Oct. 7 to determine whether the amount is “fair, reasonable and adequate,” according to a statement from the Cincinnati law firm that filed the lawsuit, Strauss & Troy.

Unfortunately for AtriCure, the latest settlement doesn’t represent the last dollar it’ll spend in the atrial fibrillation marketing foofaraw. The company has set aside $2 million to settle another class-action shareholder suit, according to its latest quarterly regulatory filing.

Fortunately for AtriCure, it expects to recover all of the losses related to the two shareholder lawsuits through insurance claims, according to the filing. Further, in agreeing to the settlement amounts, AtriCure has admitted no wrongdoing.

Aside from its legal woes, recent months have brought good news for the West Chester, Ohio-based firm. Earlier this month it reported its smallest-ever quarterly loss, posting a $764,000 loss during the second quarter. More importantly, in June AtriCure received U.S. regulatory approval to sell its AtriClip device, used during heart surgery to exclude the left atrial appendage. The exclusion helps protect atrial fibrillation patients from strokes.

The company estimates the U.S. market for the device at $150 million per year for open-heart surgeries, and that number could grow significantly if the device is approved for use in less-invasive surgeries.

Filed Under: Business/Financial News, Legal News, News Well Tagged With: AtriCure Inc.

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy